However, in a validation cohort using the ddGC regimen, changes in these DDR genes did not show a significant trend for improvement in PFS and OS [ 172 ].
← all excerpts
Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder cancer.
1
—
—